MacroGenics, Inc. (MGNX)
4.00
-0.08
(-1.96%)
USD |
NASDAQ |
Aug 28, 12:29
MacroGenics Debt to Equity Ratio : 4.624 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.624 |
| March 31, 2026 | 4.964 |
| December 31, 2025 | 1.920 |
| September 30, 2025 | 1.601 |
| June 30, 2025 | 2.306 |
| March 31, 2025 | 0.4735 |
| December 31, 2024 | 0.3228 |
| September 30, 2024 | 0.284 |
| June 30, 2024 | 0.589 |
| March 31, 2024 | 0.3204 |
| December 31, 2023 | 0.2226 |
| September 30, 2023 | 0.1758 |
| June 30, 2023 | 0.2001 |
| March 31, 2023 | 0.3162 |
| December 31, 2022 | 0.2453 |
| September 30, 2022 | 0.1791 |
| June 30, 2022 | 0.1629 |
| March 31, 2022 | 0.1366 |
| December 31, 2021 | 0.1063 |
| September 30, 2021 | 0.0911 |
| June 30, 2021 | 0.0864 |
| March 31, 2021 | 0.0815 |
| December 31, 2020 | 0.0988 |
| September 30, 2020 | 0.0976 |
| June 30, 2020 | 0.1172 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.1559 |
| December 31, 2019 | 0.1326 |
| September 30, 2019 | 0.1236 |
| June 30, 2019 | 0.0948 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| AbbVie, Inc. | -11.93 |
| Gilead Sciences, Inc. | 2.219 |
| Xencor, Inc. | 0.338 |
| Akari Therapeutics Plc | 0.0373 |
| Janux Therapeutics, Inc. | 0.0226 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 345.41M |
| Total Liabilities (Quarterly) | 302.54M |
| Shareholders Equity (Quarterly) | 42.87M |
| Current Ratio | 2.956 |
| Net Debt Paydown Yield | -10.94% |